NCT03654833 · OUTCOME

Disease Control Rate (DCR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma · Source last updated 2026-08-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: 24 weeks

What was measured

This will be assessed using CT scan evidence according to modified RECIST 1.1 criteria reporting. Scans will be undertaken every 6 weeks. Analysis will be timed from study entry using the baseline CT scan results until completion of treatment cycles, confirmed disease progression or death - whichever comes first. Complete response (CR): disappearance of all target and non-target lesions with no evidence of tumour elsewhere Partial response (PR): reduction of at least 30% in the sum of all measurements with no evidence of significant disease progression in non-target lesions or new lesions Progressive disease (PD): 1: increase of at least 20% in the sum of all measurements compared with the previous best response, 2: appearance of one or more significant (overall 20% increase in tumour diameters) new lesions, 3: significant increase in target lesions Stable disease (SD): neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD

Groups in this outcome

MiST-1

Rucaparib in DNA damage sensitive relapsed mesothelioma

MiST-2

Abemaciclib in p16INK4A negative mesothelioma

MiST-3

Pembrolizumab and bemcentinib in relapsed mesothelioma

MiST-4

Atezolizumab and Bevacizumab in relapsed mesothelioma

MiST-5

Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
MiST-1	26
MiST-2	26
MiST-3	26
MiST-4	26
MiST-5	26

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
MiST-1	6	Not reported	Not reported	Not reported	Not reported
MiST-2	6	Not reported	Not reported	Not reported	Not reported
MiST-3	10	Not reported	Not reported	Not reported	Not reported
MiST-4	7	Not reported	Not reported	Not reported	Not reported
MiST-5	8	Not reported	Not reported	Not reported	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
9
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
43.7
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG000
non Inferiority Type
OTHER
param Type
Proportion
param Value
23.1
ci Lower Limit
9
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
43.6
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG001
non Inferiority Type
OTHER
param Type
Proportion
param Value
23.1
ci Lower Limit
20.2
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
59.4
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG002
non Inferiority Type
OTHER
param Type
Proportion
param Value
38.5
ci Lower Limit
11.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
47.8
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG003
non Inferiority Type
OTHER
param Type
Proportion
param Value
26.9
ci Lower Limit
14.3
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
51.8
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG004
non Inferiority Type
OTHER
param Type
Proportion
param Value
30.8

Complete source fields

analyses

ci Lower Limit
9
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
43.7
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG000
non Inferiority Type
OTHER
param Type
Proportion
param Value
23.1
ci Lower Limit
9
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
43.6
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG001
non Inferiority Type
OTHER
param Type
Proportion
param Value
23.1
ci Lower Limit
20.2
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
59.4
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG002
non Inferiority Type
OTHER
param Type
Proportion
param Value
38.5
ci Lower Limit
11.6
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
47.8
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG003
non Inferiority Type
OTHER
param Type
Proportion
param Value
26.9
ci Lower Limit
14.3
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
51.8
group Description
The primary analysis of the primary outcome, DCR24w, will be analysed in the efficacy population. Patients will be included in the analysis if they have received at least one dose of study treatment. A total of 26 evaluable patients will be analysed for this arm. Proportion of patients with DCR will be presented with exact 95% confidence intervals.
group Ids
OG004
non Inferiority Type
OTHER
param Type
Proportion
param Value
30.8

classes

categories
measurements
group Id
OG000
value
6
group Id
OG001
value
6
group Id
OG002
value
10
group Id
OG003
value
7
group Id
OG004
value
8

denoms

counts
group Id
OG000
value
26
group Id
OG001
value
26
group Id
OG002
value
26
group Id
OG003
value
26
group Id
OG004
value
26
units
Participants

description

groups

description
Rucaparib in DNA damage sensitive relapsed mesothelioma
id
OG000
title
MiST-1
description
Abemaciclib in p16INK4A negative mesothelioma
id
OG001
title
MiST-2
description
Pembrolizumab and bemcentinib in relapsed mesothelioma
id
OG002
title
MiST-3
description
Atezolizumab and Bevacizumab in relapsed mesothelioma
id
OG003
title
MiST-4
description
Dostarlimab and Niraparib in Patients with Platinum Sensitive Relapsed Mesothelioma
id
OG004
title
MiST-5

param Type

COUNT_OF_PARTICIPANTS

reporting Status

POSTED

time Frame

24 weeks

title

Disease Control Rate (DCR) at 24 Weeks Assessed by Modified RECIST 1.1, in Patients With Relapsed Mesothelioma.

type

SECONDARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice